MARK53

With the Mark53 analysis, our company is making available a precise p53 gene test, which - for the first time - establishes the prerequisites for a broad clinical application of this biomarker. For the question, as to which patient responds to a cancer therapy and which does not, is a crucial one! We wish to pave the way for an efficient cancer therapy and continue to guarantee research that is independent of the pharmaceutical industry... Standard chemotherapy does not work as a standard instrument for all cancer patients. A targeted therapy for a few does not offer a solution either.

Also known as: MARK53 GesmbH

Registration numbers: FN 391098w (W)

VAT numbers: ATU67679915

Primary location: Wien United States